TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively. TW-37 inhibits the growth of a broad range of cancer cells (such as breast, prostate, lymphoma, and pancreatic cancer), since it induces S-phase cell cycle arrest with regulation of several important cell cycle related genes, including p27, p57, E2F-1, cdc25A, CDK4, cyclin A, cyclin D1 and cyclin E.


Cat. No.: EX-A2173	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	485	In-stock
250mg	875	In-stock
1g	1565	In-stock
5g	4695	In-stock
10g	6895	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	877877-35-5
Purity	>98%
Formula	C33H35NO6S
Mol Weight	573.699
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Zeitlin BD, et al. Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):879-87. doi: 10.1016/j.ijrobp.2010.04.024. Epub 2010 Aug 1. PubMed PMID: 20675079; PubMed Central PMCID: PMC2946486. [2]. Ashimori N, et al. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther. 2009 Apr;8(4):893-903. doi: 10.1158/1535-7163.MCT-08-1078. PubMed PMID: 19372562; PubMed Central PMCID: PMC2709836. [3]. Wang Z, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res. 2009 Apr 1;69(7):2757-65. doi: 10.1158/0008-5472.CAN-08-3060. Epub 2009 Mar 24. PubMed PMID: 19318573. [4]. Al-Katib AM, et al. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. J Hematol Oncol. 2009 Feb 16;2:8. doi: 10.1186/1756-8722-2-8. PubMed PMID: 19220884; PubMed Central PMCID: PMC2651908. [5]. Azmi AS,, et al. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther. 2008 Sep;7(9):2884-93. doi: 10.1158/1535-7163.MCT-08-0438. PubMed PMID: 18790769.
CoA	CoA of TW-37

Smiles:	CC(C)C1=CC=CC=C1CC1=C(O)C(O)=C(O)C(=C1)C(=O)NC1=CC=C(C=C1)S(=O)(=O)C1=CC=CC=C1C(C)(C)C


		Search